Shulman Joseph 4

What Happened
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals (RYTM), was granted two awards of restricted stock units (RSUs) on February 11, 2026 totaling 37,500 RSUs (15,000 + 22,500). Both grants are recorded at $0.00 (no immediate cash outlay or sale); as RSUs they are contingent rights to receive shares in the future rather than current share purchases.

Key Details

• Transaction date: February 11, 2026; filing date (Form 4): February 13, 2026 (appears timely).
• Grants: 15,000 RSUs and 22,500 RSUs, acquisition code A, reported at $0.00 (derivative awards). Total granted = 37,500 RSUs.
• Shares owned after transaction: not provided in the data you supplied.
• Footnotes:
  • F1: Each RSU = contingent right to one share of common stock.
  • F2: RSUs vest 25% on each of Feb 1, 2027; Feb 1, 2028; Feb 1, 2029; and Feb 1, 2030; RSUs have no expiration date.
  • F3: The filing also notes stock options granted on Feb 11, 2026 that vest in 16 substantially equal installments following each three-month period of service (i.e., quarterly vesting over ~4 years).

Context
RSU grants are common forms of executive compensation and do not represent an immediate purchase or sale of stock. They generally convert into actual shares only as they vest according to the schedule above. This filing documents the grant of contingent equity awards rather than a market trade; it is informational about potential future share issuance to the executive.